Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
948 USD | -0.26% |
|
+2.15% | +63.41% |
02:35pm | Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793 | MT |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.41% | 856B | |
+39.25% | 631B | |
-4.46% | 359B | |
+17.70% | 325B | |
+8.21% | 297B | |
+5.56% | 234B | |
+16.32% | 226B | |
+14.87% | 177B | |
+2.05% | 165B | |
+2.72% | 126B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Transcript : Eli Lilly and Company, Q4 2020 Earnings Call, Jan 29, 2021